The Team - Investors

Serentis is working with the following syndicate of investors:

MVM Life Science Partners LLP

MVM Life Science Partners LLP is a Venture Capital Firm, founded in 1997 and managing three funds totaling more than US$500million, that invests in companies that discover, develop and commercialise innovations in biotechnology, pharmaceuticals and medical devices for the life science and healthcare markets.  MVM has offices in both London and Boston making investments predominantly in Western Europe and the Eastern US and has a growing team with wide ranging experience across the Life Science and Private Equity markets.

For further information about MVM please visit www.mvmlifescience.com

Apposite Capital LLP

Apposite Capital is an independent investment firm focused exclusively on Healthcare. The firm primarily invests in private companies involved in Healthcare Services and Life Sciences. Apposite has an in-depth sector knowledge covering all aspects of the healthcare industry globally, with a unique unrivalled reach to Japan. The investment team combines complementary entrepreneurial, private equity and investment banking skills.

Apposite has built a high quality portfolio of companies in the US and Europe and invests across all stages of company development. Apposite typically invests as a lead investor and has a representation at the Board of Directors.  Apposite was created in 2006 and is based in London, UK.

For more information about Apposite please visit the website www.apposite-capital.com

Novo A/S

Novo A/S is the holding company of the Novo group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. Novo A/S has over US$8 billion under management, which includes significant shareholdings in the independently operating and public listed companies Novo Nordisk A/S and Novozymes A/S. Novo A/S provides venture capital for life science companies with a pioneering concept driven by high quality individuals, who seek a dedicated investment partner to help them advance towards commercialisation of ideas, products or services. Novo A/S has active investments in more than 30 European and North American life science based companies.

For more information about Novo A/S please visit www.novo.dk

East Hill Management Company

East Hill Management Company was founded as an investment firm in 2000 by Landon T. Clay and Jeffrey S. Garner to manage alternative assets for high net worth families, endowments, trusts and institutions.  East Hill is a Registered Investment Advisor with the Securities and Exchange Commission and currently manage separate accounts, a hedge fund and venture capital partnerships on behalf of clients.  East Hill venture capital partnerships have invested in 14 early stage companies spun-out of the University of Oxford, University of Cambridge, University of Southampton and University Leuven during the past five years.

For more information about East Hill please visit the website www.easthillmgt.com

Adamant Ventures Limited

Adamant Ventures Limited is the venture capital arm of Adamant Biomedical Investments, a Basle-based life sciences group which manages and advises on over US$1bn of healthcare assets. Adamant Ventures focuses on investing in private medical device and bio-pharmaceutical companies located in the UK, Scandinavia, central Europe and the US.  Adamant Ventures has been appointed by SWIP to continue the investment programme of Healthcare Private Equity LP, its healthcare venture fund which was established in 2002.

For more information about Adamant Ventures Limited please visit  www.adamantinvest.com